These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38900249)

  • 21. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
    Hamadjida A; Nuara SG; Gourdon JC; Huot P
    J Neural Transm (Vienna); 2018 Sep; 125(9):1355-1360. PubMed ID: 29247391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
    Mann E; Jackson M; Lincoln L; Fisher R; Rose S; Duty S
    J Parkinsons Dis; 2020; 10(3):959-967. PubMed ID: 32250315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 5-HT
    Kwan C; Frouni I; Bédard D; Hamadjida A; Nuara SG; Gourdon JC; Huot P
    Eur J Neurosci; 2024 Mar; 59(6):1169-1176. PubMed ID: 37515363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Veyres N; Frouni I; Kwan C; Sid-Otmane L; Harraka MJ; Gourdon JC; Huot P
    Psychopharmacology (Berl); 2017 Mar; 234(6):905-911. PubMed ID: 28130646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
    Samadi P; Grégoire L; Morissette M; Calon F; Hadj Tahar A; Bélanger N; Dridi M; Bédard PJ; Di Paolo T
    Neuropharmacology; 2008 Feb; 54(2):258-68. PubMed ID: 18001807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The highly selective 5-HT
    Hamadjida A; Nuara SG; Bédard D; Gaudette F; Beaudry F; Gourdon JC; Huot P
    Neuropharmacology; 2018 Sep; 139():61-67. PubMed ID: 29969592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
    Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
    Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the mGlu
    Kang W; Frouni I; Kwan C; Bédard D; Nuara SG; Hamadjida A; Gourdon JC; Huot P
    Eur J Neurosci; 2024 Nov; 60(9):6175-6184. PubMed ID: 38936819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The selective 5-HT
    Fisher R; Hikima A; Morris R; Jackson MJ; Rose S; Varney MA; Depoortere R; Newman-Tancredi A
    Neuropharmacology; 2020 May; 167():107997. PubMed ID: 32057799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Charvin D; Di Paolo T; Bezard E; Gregoire L; Takano A; Duvey G; Pioli E; Halldin C; Medori R; Conquet F
    Mov Disord; 2018 Oct; 33(10):1619-1631. PubMed ID: 30216534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
    Iderberg H; Maslava N; Thompson AD; Bubser M; Niswender CM; Hopkins CR; Lindsley CW; Conn PJ; Jones CK; Cenci MA
    Neuropharmacology; 2015 Aug; 95():121-9. PubMed ID: 25749357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-HT
    Kwan C; Frouni I; Bédard D; Nuara SG; Gourdon JC; Hamadjida A; Huot P
    Exp Brain Res; 2019 Feb; 237(2):435-442. PubMed ID: 30443669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.